• Login
    View Item 
    •   Home
    • UMass Chan Student Research and Publications
    • T.H. Chan School of Medicine
    • Senior Scholars Program
    • View Item
    •   Home
    • UMass Chan Student Research and Publications
    • T.H. Chan School of Medicine
    • Senior Scholars Program
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of eScholarship@UMassChanCommunitiesPublication DateAuthorsUMass Chan AffiliationsTitlesDocument TypesKeywordsThis CollectionPublication DateAuthorsUMass Chan AffiliationsTitlesDocument TypesKeywords

    My Account

    LoginRegister

    Help

    AboutSubmission GuidelinesData Deposit PolicySearchingAccessibilityTerms of UseWebsite Migration FAQ

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Mithal, Prabhakar
    Allott, Emma
    Gerber, Leah
    Reid, Julia
    Welbourn, William
    Tikishvili, Eliso
    Park, Jimmy
    Younus, Adib
    Sangale, Zaina
    Lanchbury, Jerry S.
    Stone, Steven
    Freedland, Stephen J.
    Show allShow less
    Student Authors
    Prabhakar Mithal
    Faculty Advisor
    Stephen Freedland (Duke University)
    UMass Chan Affiliations
    Senior Scholars Program
    School of Medicine
    Document Type
    Journal Article
    Publication Date
    2014-12-01
    Keywords
    Biomarkers, Tumor
    Biopsy
    Follow-Up Studies
    Humans
    Male
    Middle Aged
    North Carolina
    PTEN Phosphohydrolase
    Prognosis
    Prostatic Neoplasms
    Retrospective Studies
    Survival Rate
    Time Factors
    PTEN
    biochemical recurrence
    castration-resistant prostate cancer
    prostate cancer
    prostate cancer-specific mortality
    Clinical Epidemiology
    Neoplasms
    Urology
    Show allShow less
    
    Metadata
    Show full item record
    Link to Full Text
    http://dx.doi.org/10.1111/iju.12571
    Abstract
    OBJECTIVES: To determine whether PTEN status in prostate biopsy represents a predictor of intermediate and long-term oncological outcomes after radical prostatectomy, and whether PTEN status predicts response to androgen deprivation therapy. METHODS: In a retrospective analysis of 77 men treated by radical prostatectomy who underwent diagnostic biopsy between 1992-2006, biopsy samples were stained for PTEN expression by the PREZEON assay with > 10% staining reported as positive. Cox proportional hazards and log-rank models were used to assess the correlation between PTEN loss and clinical outcomes. RESULTS: During a median follow-up period after radical prostatectomy of 8.8 years, 39 men (51%) developed biochemical recurrence, four (5%) had castration-resistant prostate cancer, two (3%) had metastasis and two (3%) died from prostate cancer. PTEN loss was not significantly associated with biochemical recurrence (hazard ratio 2.1, 95% confidence interval 0.9-5.1, P = 0.10), but significantly predicted increased risk of castration-resistant prostate cancer, metastasis and prostate cancer-specific mortality (all log-rank, P < 0.0001), and time from androgen deprivation therapy to castration-resistant prostate cancer (log-rank, P = 0.003). No patient without PTEN loss developed metastases or died from prostate cancer. CONCLUSIONS: PTEN loss at the time of biopsy seems to predict time to development of metastasis, prostate cancer-specific mortality and, for the first time, castration-resistant prostate cancer and response to androgen deprivation therapy after radical prostatectomy. If confirmed by larger studies, this would support the use of PTEN loss as an early marker of aggressive prostate cancer.
    Source
    Int J Urol. 2014 Dec;21(12):1209-14. doi: 10.1111/iju.12571. Epub 2014 Aug 5. Link to article on publisher's site
    DOI
    10.1111/iju.12571
    Permanent Link to this Item
    http://hdl.handle.net/20.500.14038/49269
    PubMed ID
    25099119
    Notes

    Prabhakar Mithal participated in this study as a medical student as part of the Senior Scholars research program at the University of Massachusetts Medical School.

    Related Resources
    Link to Article in PubMed
    ae974a485f413a2113503eed53cd6c53
    10.1111/iju.12571
    Scopus Count
    Collections
    T.H. Chan School of Medicine Student Publications
    Senior Scholars Program

    entitlement

    Related items

    Showing items related by title, author, creator and subject.

    • Thumbnail

      Prostate Cancer: Advances in Radiation Oncology, Molecular Biology, and Future Treatment Strategies

      Wang, Tao; Lewis, Brian; Ruscetti, Marcus; Mittal, Kriti; Wang, Ming-Jin; Sokoloff, Mitchell H.; Ding, Linda; Bishop-Jodoin, Maryann; FitzGerald, Thomas J. (2022-09-12)
      Prostate cancer remains an important health problem worldwide affecting one in every six men including members of vulnerable communities. Although successful treatments have been delivered to men affected with the disease resulting in improved patient outcome, process improvements including therapy titration and augmentation are needed to optimize tumor control and limit normal tissue injury from therapy. In this chapter, we describe current management strategies for optimal patient care with radiation therapy and opportunities for improvement of care moving forward with applied science to apply therapy in a strategic manner, potentially improving care and outcome for patients treated for this disease.
    • Thumbnail

      Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database

      Mithal, Prabhakar; Howard, Lauren E.; Aronson, William J.; Kane, Christopher J.; Cooperberg, Matthew R.; Terris, Martha K.; Amling, Christopher L.; Freedland, Stephen J. (2015-04-01)
      OBJECTIVES: To assess the ability of preoperative prostate-specific antigen level, Gleason score and stage to predict prostate cancer outcomes beyond biochemical recurrence, specifically castration-resistant prostate cancer, metastases and prostate cancer-specific mortality in radical prostatectomy patients. METHODS: We carried out a retrospective study of 2735 men in the Shared Equal Access Regional Cancer Hospital database treated by radical prostatectomy from 1988 to 2011 with data available on pathological stage, grade and preoperative prostate-specific antigen. We used Cox hazards analyses to examine the predictive accuracy (c-index) of the preoperative prostate-specific antigen (log-transformed), path Gleason score ( < /= 7, 3 + 4, 4 + 3 and 8-10) and path stage grouping (pT2 negative margins; pT2 positive margins; pT3a negative margins; pT3a positive margins; pT3b; vs positive nodes) to predict biochemical recurrence, castration-resistant prostate cancer, metastases and prostate cancer-specific mortality. RESULTS: Median follow up was 8.7 years, during which, 937 (34%) had biochemical recurrence, 108 (4%) castration-resistant prostate cancer, 127 (5%) metastases and 68 (2%) prostate cancer-specific mortality. For the outcomes of biochemical recurrence, castration-resistant prostate cancer, metastases and prostate cancer-specific mortality, the c-indices were, respectively: prostate-specific antigen 0.65, 0.66, 0.64 and 0.69; Gleason score 0.66, 0.83, 0.76 and 0.85; and pathological stage group 0.69, 0.76, 0.72 and 0.80. CONCLUSIONS: Gleason score can predict with very high accuracy prostate cancer-specific mortality in patients undergoing radical prostatectomy. Thus, Gleason score should be given more weight in nomograms to predict prostate cancer-specific mortality. Furthermore, men with a high Gleason score should be given special consideration for adjuvant treatment or referral to clinical trials because of a higher risk of prostate cancer-specific mortality.
    • Thumbnail

      UMass PCORI PSA decision aid [English]

      Saver, Barry G.; Bacigalupe, Gonzalo; Esparza, Nancy; Cutrona, Sarah L.; Hayes, Marcela; Gorodetsky, Tatyana; Mazor, Kathleen M.; Calista, Joanne; Luckmann, Roger S. (2015-06-10)
      This is a presentation developed as a decision aid to help consumers understand the May 2012 recommendations of the US Preventive Services Task Force against routine prostate cancer (PSA) screening and why that might be the right choice for them. This decision aid was produced in 2013-2014 under research contract 1IP2PI000633 from the Patient-Centered Outcomes Research Institute (PCORI) to the University of Massachusetts Medical School by personnel from: The University of Massachusetts Medical School, the University of Massachusetts Boston, and the Central Massachusetts Area Health Education Center.
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Lamar Soutter Library, UMass Chan Medical School | 55 Lake Avenue North | Worcester, MA 01655 USA
    Quick Guide | escholarship@umassmed.edu
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.